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Received March 2, 2011; accepted August 11, 2011AbstractBackground: The aim of our study was to identify the optimal predictor of prostate cancer among several prostate-specific antigen (PSA)
derivatives in repeat prostate biopsy.
Methods: We retrospectively assessed the repeat prostate biopsy specimens, obtained between 1999 and 2008, of 212 patients with a total PSA
(tPSA) of 4e10 ng/ml and normal digital rectal examination. Using a receiver operating characteristic (ROC) analysis, we assessed the
predictive power of tPSA, percent free PSA (f/t PSA), PSA density (PSAD), and PSA velocity (PSAV) for the detection of prostate cancer.
Results: Repeat prostate biopsy specimens were positive for prostate cancer in the case of 26 patients and negative in the case of 186 patients.
The areas under the receiver operating characteristic (ROC) curves for tPSA, f/tPSA, PSAD, and PSAV were 72.7%, 57.9%, 74.4%, and 64.8%,
respectively. The ROC curve analysis revealed that PSAD was a better predictor of prostate cancer than f/t PSA. Moreover, when PSAD at an
optimal cutoff of 0.18 ng/ml/cc was considered as the predictor, the detection of prostate cancer was found to have a high sensitivity and
specificity (77% and 69%, respectively).
Conclusion: In a repeat prostate biopsy, PSAD is superior to f/t PSA as a predictor of prostate cancer. And, by assessing this predictor, an
unnecessary repeat biopsy of patients with tPSA of 4e10 ng/ml can be avoided.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Prostate cancer is a very common type of cancer in the
United States and most western countries, but it is not as
prevalent in Asian countries.1,2 During the past decade,
however, the incidence of prostate cancer in Taiwan has been
rising year after year. According to data from the Taiwan
Cancer Registry, the incidence of prostate cancer in 2006 was
ranked fifth among leading invasive cancers. Prostate cancer is
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doi:10.1016/j.jcma.2011.10.004of prostate-specific antigen (PSA) in clinical practice, a digital
rectal examination (DRE) was the most common method for the
detection of prostate cancer. Serum total PSA (tPSA) is a useful
serummarker for the early detection of prostate cancer.3 Several
studies have indicated that the serum tPSA cutoff level of 4 ng/
ml should be used for the screening of prostate cancer.4 Our
current study was no exception. In a patient with abnormal
serum tPSA levels or palpable nodules during a DRE, prostate
biopsy is performed to confirm the diagnosis of prostate cancer.
If the initial biopsy result reveals no malignancy, a repeat biopsy
for those patients with persistently abnormal tPSA or DRE may
be performed later.
A serum tPSA level between 4 and 10 ng/ml is considered
as the diagnostic gray zone,5 because these levels may be
indicative of either prostate cancer or benign prostatichinese Medical Association. All rights reserved.
Table 1
Age, prostate volume, and PSA results of 212 patients diagnosed with prostate
cancer or benign prostatic hyperplasia after repeat prostate biopsy.
BPH prostate Cancer p value
Number of patients 186 26
Age 66.59  9.92 73.42  3.81 < 0.001
Total prostate volume (ml) 42.81  18.15 32.75  10.76 0.008
tPSA (ng/ml) 6.34  1.66 7.37  1.24 0.001
fPSA (ng/ml) 1.31  0.65 1.64  1.60 0.663
f/tPSA (%) 21.41  8.83 21.72  21.59 0.148
PSAD (ng/ml/cc) 0.182  0.203 0.252  0.099 < 0.001
PSAV (ng/ml/yr) 0.263  1.713 0.832  0.924 0.008
BPH ¼ benign prostatic hyperplasia; fPSA ¼ free PSA; f/t PSA ¼ percent free
PSA; PSA ¼ prostate-specific antigen PSAD ¼ PSA density; PSAV ¼ PSA
velocity; tPSA ¼ total PSA.
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patients with gray-zone serum tPSA and normal findings of
DRE implied that considering only serum tPSA as the
predictive factor in repeat prostate biopsy can result in a high
rate of false negative prediction of prostate cancer. Therefore,
increasing the sensitivity and the specificity of the serum tPSA
testing is important to avoid unnecessary repeat prostate
biopsy, which is invasive and costly. We retrospectively
reviewed our database of prostate biopsies and sought to
evaluate the predictive power of tPSA, percent free PSA (f/t
PSA), PSA density (PSAD), and PSA velocity (PSAV).
2. Methods
From April 1999 to February 2008, 2987 patients (3625
prostate biopsies) underwent transrectal ultrasound (TRUS)-
guided prostate biopsy in our hospital. Of these patients, 417
with elevated serum tPSA or abnormal DRE findings under-
went repeat prostate biopsy. We excluded patients with
abnormal DRE findings and serum tPSA levels > 10 ng/ml.
Finally, 212 men with serum tPSA levels of 4e10 ng/ml and
normal DRE findings were included for the statistical analysis.
TRUS-guided prostate biopsy was performed using an 18-G
needle. The number of core biopsy specimens in the first and
second TRUS-guided prostate biopsy was the same. The
number was between 8 and 14. The total prostate volume was
measured using TRUS. PSAD was calculated as tPSA divided
by total prostate volume.6
Serum tPSA and free PSA (fPSA) were measured using
TPSA-RIACT and FPSA-RIACT kits (CIS-Bio International,
France), respectively. The f/tPSA was calculated as fPSA
divided by tPSA.7 For the determination of PSAV, the latest
three values of tPSA were obtained, and PSAV was calculated
using linear regression.8
3. Statistical analysis
Mann-Whitney U test was used to compare continuous data
groups, and a p value less than 0.05 were considered statisti-
cally significant. The sensitivity and specificity were calcu-
lated for the overall study population. The ROC curves were
prepared for each PSA derivative. The areas under the ROC
curves were used to assess the accuracy of each test with PSA
derivatives, and they were compared using the Mann-Whitney
U test as modified by Bonferonni-Holm. The p values less than
0.05 were considered statistically significant.
4. Results
At our institution, the positive rates of prostate cancer
detection in the first and second TRUS-guided prostate biopsy
were 26.6% (795 of 2987) and 13.3% (63 of 474), respec-
tively. Of the 212 patients with tPSA of 4e10 ng/ml and
normal DRE who underwent repeat prostate biopsy, 26
patients (12.3%) were diagnosed with prostate cancer. Table 1
shows the patient age, total prostate volume, tPSA, fPSA, f/t
PSA, PSAV, and PSAD. The values of tPSA, PSAD, and PSAVof patients diagnosed with prostate cancer were significantly
higher than those patients diagnosed with BPH (Mann-Whit-
ney U test, p ¼ 0.001, 0.000005, and 0.008, respectively).
However, the values of fPSA and f/t PSA in both groups were
not significantly different ( p ¼ 0.663 and 0.148, respectively).
The predictive ability of each PSA derivative in repeat
prostate biopsy was analyzed using the ROC curves (Fig. 1.
The areas under the ROC curves for each PSA derivative and
their 95% confidence intervals are shown in Table 2. The areas
under the curves for tPSA, f/tPSA, PSAD, and PSAV were
72.7%, 57.9%, 74.4%, and 64.8%, respectively. Comparison of
f/t PSA, PSAV, or PSAD with tPSA revealed no statistically
significant difference (Mann-Whitney U test as modified by
Bonferroni-Holm, p ¼ 0.106, 0.323, and 0.825, respectively).
PSAD was observed to be a significantly better predictor of
prostate cancer than f/t PSA (Mann-Whitney U test as modi-
fied by Bonferroni-Holm, p ¼ 0.023).
To increase the specificity of repeat biopsy and to avoid
unnecessary repeat biopsy, cutoffs that ensured good speci-
ficity and sufficiently high sensitivity were selected. Table 3
shows that optimal cutoffs of 6.44 ng/ml, 25%, 0.75 ng/ml/
year and 0.18 ng/ml/cc for tPSA, f/t PSA, PSAV, and PSAD,
respectively, were the most accurate in predicting positive
repeat biopsy. The sensitivity and specificity of these optimal
cutoffs are also shown in Table 3.5. Discussion
Prostate biopsy is the gold standard for diagnosing prostate
cancer in men with elevated serum tPSA levels or abnormal
DRE findings. Earlier, a sextant prostate needle biopsy was
widely used for establishing the definitive diagnosis in patients
suspected of having prostate cancer.9 However, a 1998 study
revealed that the false negative rate of prostate cancer detec-
tion by this method was 30%.9 Thereafter, many studies rec-
ommended that the number of core biopsy specimens should
be increased during repeat prostate biopsy.10,11 However, the
optimal number of core biopsy specimens still remains
controversial. In our study, we increased the number of core
biopsy specimens from eight to 14 cores. Repeat prostate
biopsy plays an important role in patients whose initial biopsy
Fig. 1. ROC curves for prostate cancer detection in repeat prostate biopsy. tPSA (yellow), f/tPSA (yellow dash), PSAD (red), PSAV (purple).
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identify markers to eliminate the need for repeat prostate
biopsy, which is invasive and costly. We retrospectively eval-
uated the ability of tPSA, f/t PSA, PSAV, and PSAD to predict
the results of repeat prostate biopsy.
Yang and colleagues conducted a prospective blinded study
of patients with serum tPSA between 4 and 25 ng/ml by using
f/tPSA for prostate cancer detection.12 Optimal cutoff set at
30% could eliminate 30%e36% of unnecessary biopsies and
ensure a reasonable sensitivity. However, this cutoff may not
be suitable for patients who have already undergone prostate
biopsy. When we set a cutoff of f/t PSA at 30% for our
patients, the sensitivity and specificity of the test were
observed to be 25% and 84%, respectively. This degree of
sensitivity was not acceptable. Therefore, we observed that if
the optimal cutoff of f/tPSA was set at 25%, then the sensi-
tivity and specificity of this variable in the detection of pros-
tate cancer were 65% and 53%, respectively. On the basis ofTable 2
Areas under the ROC curves of the PSA derivatives in repeat prostate biopsy.
Area under the ROC
Mean  SD (95% CI)
tPSA
p value*
f/tPSA
p value*
tPSA (ng/ml) 0.727  0.0674 (0.647e0.797) d 0.106
f/tPSA (%) 0.579  0.066 (0.494e0.660) 0.106 d
PSAD (ng/ml/cc) 0.744  0.0663 (0.666e0.813) 0.825 0.023
PSAV (ng/ml/yr) 0.648  0.0706 (0.565e0.725) 0.323 0.461
f/t PSA ¼ percent free PSA; PSA ¼ prostate-specific antigen PSAD ¼ PSA
density; PSAV ¼ PSA velocity; tPSA ¼ total PSA; ROC ¼ receiver operating
characteristic.
* Comparison with tPSA or f/tPSA.the above mentioned results, we considered that f/tPSA is not
ideal for use as a predictor of prostate cancer.
Djavan and colleagues13 reported a prospective study of
1051 men with serum tPSA levels of 4e10 ng/ml. The positive
rates of prostate cancer detection during the initial prostate
biopsy and repeat biopsy were 22% (231 of 1051) and 10%
(83 of 820), respectively. In these patients, f/t PSA and
transitional-zone PSAD were the most accurate predictors of
prostate cancer. They suggested that a repeat prostate biopsy
of patients with f/t PSA levels less than 30% or transitional-
zone PSAD of 0.26 ng/ml/cc or greater should be per-
formed. In our study, the transitional-zone prostate volume
was not measured for all of the included patients because the
measurement bias of the transitional-zone volume in small-
sized prostate (< 30 cc) was significant.14 In our patients,
the transitional-zone PSAD was not found to be superior to
PSAD when compared with both of the ROC curves. PSAD
was significantly better than f/t PSA as a predictor of a positive
result of a repeat prostate biopsy. Our results were different
from those of Djavan and others but similar to those of ShenTable 3
PSA results at optimal cutoffs for 212 patients after repeat prostate repeat
biopsy.
Optimal cutoff Sensitivity (%) Specificity (%)
tPSA (ng/ml) 6.44 81 61
f/tPSA (%) 25 65 53
PSAD (ng/ml/cc) 0.18 77 69
PSAV (ng/ml/yr) 0.75 65 70
f/t PSA ¼ percent free PSA; PSA ¼ prostate-specific antigen PSAD ¼ PSA
density; PSAV ¼ PSA velocity; tPSA ¼ total PSA.
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clinical diagnostic value than f/tPSA for the diagnosis of
prostate cancer in Chinese patients with tPSA level in the
diagnostic gray zone. The differences between the patients of
Asian and Caucasian descent may be attributed to the biologic
aspects of ethnicity.
Vickers and colleagues16 reported a systematic review of
pretreatment PSAV and doubling time as predictors for pros-
tate cancer, showing that there is little evidence that the
calculation of PSAV and doubling time in untreated patients
provides predictive information beyond that provided by only
tPSA level. In our study, the area under the ROC curve of
PSAV was compared with those of tPSA, PSAD, and f/tPSA
(Mann-Whitney U test, p ¼ 0.323, 0.282 and 0.461, respec-
tively). We observed that PSAV was not a better predictor than
other PSA derivatives. Our results were consistent with those
of Vickers and others.16
An ideal test should have a high sensitivity and a high
specificity, but such tests may not exist in the real world. Tests
used to screen patients for cancer should be highly sensitive.
This is because although cancer is associated with high
mortality, it is curable if it is diagnosed in its early stages. In
tests performed for lethal communicable diseases, such as
human immunodeficiency virus, false positive results can lead
to serious consequences. Therefore, in such cases, the tests
should be highly specific. We used a serum tPSA level of
4 ng/ml as the cutoff for prostate cancer screening because this
value has been shown to have a high sensitivity. However, using
only a serum tPSA test would not be sufficient for further
follow-up and the evaluation of the possibility of prostate
cancer if the initial prostate biopsy showed BPH. Therefore, the
specificity of this test is important to avoid an unnecessary
repeat prostate biopsy. We need optimal cutoffs for these tests
with the same weighting of sensitivity and specificity. Two
methods are commonly used to identify the optimal cutoffs of
tests.17,18 In our protocol, we considered the values closest to
the (0,1) point on the ROC curve as the optimal cutoffs that
corresponded to the specificity and sensitivity values. These
values were considered as the best differentiators between
people with disease and those without disease.17,18
6. Limitations
First, we included patients with serum tPSA levels of
4e10 ng/ml and normal DRE findings, so the final conclusions
could not be generalized to all repeat biopsy patients. Secondly,
prostate volumes of all study patients were measured by
multiple operators. Therefore, inter-operator bias might inter-
fere with our results. Additionally, this was a retrospective
study, so various biopsy intervals and different numbers of
biopsy core were noted. However, there were no definite
guidelines for these two issues. Thirdly, our small sample size
and long study period could cause some biases. Further
prospective studies with large sample sizes and meticulous
designs will overcome these shortcomings.
In conclusion, we propose that PSAD is superior to f/t PSA
as a predictor of prostate cancer in repeat prostate biopsy formen with serum tPSA levels of 4e10 ng/ml. Using the optimal
cutoff (0.18 ng/ml/cc) for PSAD, we can avoid unnecessary
prostate biopsies and obtain an acceptable positive rate of
prostate cancer detection from the core biopsy specimens.References
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